Published in World J Gastroenterol on January 28, 2014
Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol (2015) 0.92
Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget (2016) 0.78
Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther (2016) 0.75
A 19-Gene expression signature as a predictor of survival in colorectal cancer. BMC Med Genomics (2016) 0.75
Epigenetics in diagnosis of colorectal cancer. Mol Biol Res Commun (2016) 0.75
Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors. Onco Targets Ther (2017) 0.75
The case for early detection. Nat Rev Cancer (2003) 6.96
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med (1996) 4.46
Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer (2005) 4.43
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology (2005) 2.71
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
A roadmap to generate renewable protein binders to the human proteome. Nat Methods (2011) 2.38
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut (2013) 2.17
Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist (2008) 2.10
Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev (2007) 2.00
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med (2011) 1.93
Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology (2011) 1.86
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol (2000) 1.74
A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer (2010) 1.70
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut (2012) 1.63
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging (2003) 1.47
Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One (2012) 1.35
Colorectal cancer screening--optimizing current strategies and new directions. Nat Rev Clin Oncol (2013) 1.35
Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin Appl (2010) 1.35
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res (2008) 1.32
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res (2000) 1.27
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med (2010) 1.26
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
In biomarkers we trust? Nat Biotechnol (2005) 1.24
Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg (2013) 1.23
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol (2005) 1.20
The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol (2011) 1.19
Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol (2007) 1.19
Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol (2010) 1.18
Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep (2008) 1.18
Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res (2003) 1.16
A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev (2006) 1.14
A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res (2010) 1.13
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res (2012) 1.11
Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis (2008) 1.09
Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res (2007) 1.07
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol (2008) 1.06
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem (2012) 1.05
Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen (2011) 1.04
Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am J Gastroenterol (2010) 1.02
Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes (2006) 1.01
Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev (2013) 1.01
Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res (2001) 1.01
Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta (2007) 0.96
Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab (1991) 0.95
Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer (2012) 0.95
Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer. Cancer Immunol Immunother (2000) 0.93
A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res (2010) 0.92
New paradigms in translational science research in cancer biomarkers. Transl Res (2012) 0.92
Determination of tumor markers in serum. Pitfalls and good practice. Clin Chem Lab Med (2001) 0.91
Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark (2010) 0.91
The European Prospective Investigation into Cancer and Nutrition biobank. Methods Mol Biol (2011) 0.90
Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today (2003) 0.90
Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin Chem Lab Med (2009) 0.89
Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer (2004) 0.87
A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control (2012) 0.87
Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol (2006) 0.86
Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer. Cancer Biomark (2013) 0.83
CA 19-9: handle with care. Clin Chem Lab Med (2013) 0.81
Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark (2013) 0.80
Longitudinal changes in IGF-I and IGFBP-3, and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev (2013) 0.79